Scientists are working on a new way to deliver a natural compound called CBD (from cannabis plants) directly to breast cancer cells. The problem is that CBD doesn’t work well when taken by mouth because the body doesn’t absorb it properly. Researchers created tiny packages called exosomes to carry CBD into the body and deliver it right to cancer cells. In lab tests and animal studies, this new delivery method was much better at stopping cancer growth, especially for a difficult-to-treat type called triple-negative breast cancer. The packaged CBD also caused fewer side effects by targeting cancer cells specifically rather than harming healthy cells.
The Quick Take
- What they studied: Whether wrapping CBD (a cannabis compound) in tiny natural packages called exosomes could deliver it better to breast cancer cells and work more effectively than regular CBD
- Who participated: The study used cancer cells grown in labs (including triple-negative breast cancer cells and regular breast cancer cells) and mice with human breast cancer tumors implanted in them
- Key finding: The packaged CBD, especially when labeled with folic acid to target cancer cells, was significantly better at stopping cancer growth and caused less damage to healthy cells compared to regular CBD or unpackaged CBD
- What it means for you: This research suggests a potential new treatment approach for breast cancer patients, particularly those with hard-to-treat triple-negative breast cancer. However, this is early-stage research—human clinical trials would be needed before this could become an actual treatment option. Talk to your doctor about current approved breast cancer treatments.
The Research Details
Scientists created tiny delivery packages called exosomes (which are natural particles your body already makes) and loaded them with CBD. They tested two versions: regular exosomes with CBD and exosomes tagged with folic acid (a B vitamin) to help them find cancer cells more easily. They tested these packages on different types of breast cancer cells grown in dishes, including a very aggressive type called triple-negative breast cancer. They also tested how well the packages survived in conditions that mimic your stomach and intestines. Finally, they implanted human breast cancer tumors into mice and gave them the packaged CBD by mouth to see if it worked better than regular CBD.
The researchers measured how well the exosomes protected the CBD, how much CBD was released in the right places, and how effectively the treatment stopped cancer growth. They also analyzed which genes were turned on or off in the cancer cells after treatment to understand how the medicine was working.
One of the biggest challenges with CBD as a cancer treatment is that when you swallow it, your body doesn’t absorb much of it—most gets destroyed before it can reach cancer cells. By packaging it in exosomes, scientists can protect the CBD during digestion and deliver it directly to tumors. This approach could mean patients need smaller doses with fewer side effects, making treatment safer and more effective.
This is laboratory and animal research, which is an important first step but not yet proven in humans. The study was thorough in testing multiple cancer cell types and included animal models with actual tumors. The researchers measured many different outcomes and analyzed gene changes to understand how the treatment worked. However, results in mice don’t always translate to humans, and human clinical trials would be needed to confirm safety and effectiveness.
What the Results Show
The packaged CBD formulations successfully protected the CBD as it traveled through simulated stomach and intestinal conditions, releasing the medicine gradually in the right places. The folic acid-tagged exosomes were about 136 nanometers in size (extremely tiny—invisible to the naked eye) and maintained their structure throughout the process.
When tested on cancer cells in dishes, the packaged CBD was more effective at stopping cancer growth, especially against triple-negative breast cancer cells, which are normally very aggressive and hard to treat. Regular breast cancer cells (ER+ type) were less sensitive to the treatment, suggesting the medicine works best against certain types of breast cancer.
In mice with breast cancer tumors, the folic acid-tagged packaged CBD was significantly better at reaching tumors, staying in tumors longer, and stopping tumor growth compared to regular CBD or unpackaged CBD. This means the targeting system actually worked—the medicine found the cancer cells.
Gene analysis showed that the packaged CBD turned off genes that help cancer cells survive and turned on genes that fight cancer. Importantly, it reduced genes associated with cancer spreading to the lungs, which is a major concern in breast cancer treatment.
The study found that the packaged CBD reduced inflammation markers in cancer cells, which is important because inflammation helps cancer grow. The medicine also triggered cancer cells to die through a process called apoptosis (programmed cell death). The folic acid tagging system proved valuable—it helped the exosomes find and stick to cancer cells more effectively than untagged packages. Over 1,000 genes were affected by the treatment, showing the medicine works through multiple pathways in the body.
Previous research showed that CBD has anti-cancer properties, but the challenge has always been getting enough of it into the body and to the right place. This study builds on that knowledge by solving the delivery problem. Other researchers have tried different delivery systems for cancer drugs, but using exosomes (which are natural particles your body already produces) is a promising approach because it may cause fewer side effects than artificial delivery systems.
This research was done in laboratory dishes and mice, not in humans. Mouse studies don’t always produce the same results in people. The study didn’t test how long the effects last or whether cancer cells might develop resistance over time. The exact dose needed for humans and potential side effects in people are unknown. The research also didn’t compare this approach to standard breast cancer treatments like chemotherapy or radiation. Additionally, the sample size for animal studies wasn’t specified, and we don’t know if results would be consistent across different patient populations.
The Bottom Line
This research is promising but very early-stage. Current breast cancer patients should continue with proven treatments recommended by their oncologists. For people interested in CBD for other purposes, talk to your doctor—this research doesn’t yet support using CBD as a breast cancer treatment outside of clinical trials. If you have triple-negative breast cancer, ask your doctor about clinical trials testing new delivery methods for cancer drugs.
This research is most relevant to people with triple-negative breast cancer, which is harder to treat with standard therapies. It’s also important for researchers developing new cancer treatments and for pharmaceutical companies looking for better drug delivery methods. People with other types of breast cancer may benefit eventually, but the research specifically showed better results for triple-negative types. This doesn’t currently apply to people without cancer.
This is very early research. If this approach moves forward, it would typically take 5-10 years of additional testing before it could potentially become available as a treatment. Clinical trials in humans would need to happen first to confirm it’s safe and effective. Don’t expect this treatment to be available soon, but it represents promising progress in cancer research.
Want to Apply This Research?
- For users interested in cancer research developments: Track clinical trial announcements and research milestones related to CBD-based cancer treatments. Set reminders to check ClinicalTrials.gov quarterly for new trials testing exosome-based cancer therapies.
- Users can use the app to log conversations with their oncologist about emerging treatments and clinical trial eligibility. Create a ‘Research Interest’ section to track which cancer research areas are most relevant to their health situation and set notifications for updates in those areas.
- Establish a long-term tracking system for cancer research developments in specific areas of interest. Users can set quarterly check-ins to review new publications and clinical trial opportunities. For those currently in treatment, track how emerging research might affect future treatment decisions by maintaining a timeline of research milestones.
This research describes early-stage laboratory and animal studies, not human clinical trials. These findings do not constitute medical advice or approval for human use. Breast cancer patients should continue working with their oncologists on proven treatment options. CBD is not an approved breast cancer treatment by the FDA. Do not use CBD as a substitute for standard cancer treatment without consulting your doctor. Clinical trials would be needed to determine safety and effectiveness in humans. If you have breast cancer or are interested in clinical trials, speak with your healthcare provider about options appropriate for your specific situation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.